{"id":731961,"date":"2025-02-17T17:14:02","date_gmt":"2025-02-17T17:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=731961"},"modified":"2025-02-17T17:14:02","modified_gmt":"2025-02-17T17:14:02","slug":"ameracell-partners-with-stemwave-to-offer-innovative-pain-management-solutions","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ameracell-partners-with-stemwave-to-offer-innovative-pain-management-solutions_731961.html","title":{"rendered":"AmeraCell Partners with StemWave to Offer Innovative Pain Management Solutions"},"content":{"rendered":"

\"\"<\/strong><\/em><\/p>\n

Fairfax, VA –<\/strong> AmeraCell, a leading provider of life science medicines, is pleased to announce that it has signed a Letter of Intent (LOI) with StemWave, a pioneering provider of non-invasive pain management solutions.<\/p>\n

This strategic partnership aims to provide patients with cutting-edge regenerative medicine solutions for pain management, leveraging the expertise of both organizations.<\/p>\n

“We are thrilled to partner with StemWave to offer our patients innovative pain management options,” said Dr. Doki, Chief Medical Officer of AmeraCell. “This partnership reflects our commitment to providing the most advanced and effective treatments for pain management in Fairfax, Virginia.”<\/p>\n

“AmeraCell is proud to collaborate with StemWave, a respected leader in pain management,” said AJ Pakpour, Founder of AmeraCell. “Together, we will work to improve the lives of patients suffering from chronic pain, offering them new hope and innovative solutions utilizing StemWave therapy in conjunction with our MSC and Exosomes products.”<\/p>\n

The partnership will enable both organizations to expand their services, providing patients with access to a broader range of regenerative medicine solutions, including stem cell injections and stem cell IV treatments in Fairfax Virginia.<\/p>\n

About AmeraCell<\/strong><\/p>\n

AmeraCell is a leading provider of life science medicines with multiple national locations, dedicated to improving the lives of patients through innovative and effective treatments, one cell at a time.<\/p>\n

About StemWave<\/strong><\/p>\n

StemWave therapy is a non-invasive treatment that uses acoustic wave technology to stimulate the body’s natural healing processes. It is also known as shock wave therapy.<\/p>\n

StemWave therapy delivers high-energy sound waves to the affected area, promoting:<\/strong><\/p>\n

– Increased blood flow<\/p>\n

– Improved cell regeneration<\/p>\n

– Reduced inflammation<\/p>\n

Conditions Treated:<\/strong><\/p>\n

StemWave therapy is commonly used to treat musculoskeletal conditions such as:<\/strong><\/p>\n

– Chronic pain<\/p>\n

– Plantar fasciitis<\/p>\n

– Tendinitis<\/p>\n

– Arthritis<\/p>\n

– Osteoporosis<\/p>\n

Note to editors:<\/strong><\/p>\n

– High-resolution images and interviews with Dr. Doki and AJ Pakpour are available upon request.<\/p>\n

– For more information about AmeraCell, please visit<\/p>\n

AmeraCell.com<\/strong><\/p>\n

AmeraCellClinics@Gmail.com<\/p>\n

407 801 2269<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> AmeraCell<\/a>
Email:<\/strong> Send Email<\/a>
Address:<\/strong>3022 Williams Dr
City:<\/strong> Fairfax
State:<\/strong> Virginia 22031
Country:<\/strong> United States
Website:<\/strong> https:\/\/ameracell.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Fairfax, VA – AmeraCell, a leading provider of life science medicines, is pleased to announce that it has signed a Letter of Intent (LOI) with StemWave, a pioneering provider of non-invasive pain management solutions. This strategic partnership aims to provide … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,404],"tags":[],"class_list":["post-731961","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/731961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=731961"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/731961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=731961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=731961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=731961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}